Company: GRCE
Filing Date: 2025-02-10
Form Type: 8-K
Source: 0001140361-25-003645
Chunk: 4

Company: Grace Therapeutics, Inc.
Filing Date: 2025-02-10
Form: 8-K
Item: Item 8.01
Chunk 4
---
Item 8.01.      Other Events.  

On February 10, 2025, the Company issued a press release announcing the top line results of the pivotal Phase 3 STRIVE-ON safety trial. The Phase 3
STRIVE-ON Safety trial met its primary endpoint and provided evidence of clinical benefit over orally administered nimodipine. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

On February 10, 2025, the Company posted an updated investor presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.2
and is incorporated by reference into this Item 8.01.

On February 10, 2025, the Company issued a press release announcing the Offering. A copy of
the press release is attached hereto as Exhibit 99.3 and is incorporated by reference into this Item 8.01.